NASDAQ:ATHE

Appendix 4C - Q4 FY21 Quarterly Cash Flow Report

Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...

2021-07-30 21:05 1968

Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function

MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced thatMovement Disorders, the official jou...

2021-07-15 21:52 35679

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's

MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).  The patent secures a ...

2021-07-01 19:50 12432

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Highlights: * Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. * Concurrence with Alterity's plan to target early stage MSA patients. * Endorsement on selection ...

2021-06-23 21:21 13931

Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

Highlights: * Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation * Strengthening profile at investment, scientific and clinical conferences * Dr David Stamler appointed Chief Executive Officer * Cash balance as at 31 March 2021 of A$32.8M MELBOURN...

2021-04-29 20:30 4894

ATH434 protects brain cells and improves motor function in Parkinsonian disorder

MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of...

2021-04-21 20:11 1630

Alterity to present at the 7th International Congress of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...

2021-02-26 20:45 5166

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's di...

2021-02-09 21:53 2710

Dr David Stamler Appointed CEO

MELBOURNE, Australia, Jan. 7, 2021 /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of DrDavid Stamler to the role of Chief Executive Office effective immediately. Dr Stamler joined the Company in J...

2021-01-07 21:00 10849

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to ...

2020-12-22 05:42 4854

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...

2020-11-17 01:09 698

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-ho...

2020-11-16 21:42 2150

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...

2020-10-27 10:03 2867

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

MELBOURNE, Australia and SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for present...

2020-08-04 09:33 6918

Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report

Highlights: * FDA provides guidance for ATH434 development pathway * Company compliant with minimum NASDAQ price * End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July MELBOURNE, Australia and SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- Alterity Therap...

2020-07-31 06:49 16292

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 ...

2020-06-30 11:14 5257

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

MELBOURNE, Austrilia and SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting....

2020-05-21 08:58 5030

Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report

Highlights: * European Commission designated Orphan Drug status for ATH434's treatment of Multiple System Atrophy in the European Union * Phase 2 preparatory work continues * Cash balance of $10.4M MELBOURNE, Australia and SAN FRANCISCO, April 30, 2020 /PRNewswire/ -- Alterity Therapeutics ...

2020-04-30 16:35 10154

Alterity Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

MELBOURNE, Australia and SAN FRANCISCO, Feb. 7, 2020 /PRNewswire/ -- Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed se...

2020-02-07 21:00 10734